The GMP cytokines market is expected to reach US$ 158.13 million in 2027 from US$ 84.72 million in 2019; it is estimated to grow at a CAGR of 8.1% from 2020 to 2027. The growth of the GMP cytokines market is mainly attributed to increase in acceptance of cytokines cancer and autoimmune therapies and potential contribution in the stem cell therapy. However, high cost associated with GMP cytokines therapy is projected to deter the market growth.
Stem cell research has been widely investigated globally to improve the quality of human health.The stem cells play a prominent role in replacement and reconstruction of damaged tissues.
Based on extensive research on stem cells, many scientists have appealed that the cells could probably generate novel therapies for various chronic diseases, such as cardiovascular disease and cancers.With the advent of new technologies and research, the cytokines growth factor is also contributing to the utilization of stem cells for novel therapeutics.
Hematopoietic stem cell therapy cytokines (growth factors) play a major role in the regulation of multiple parameters of hematopoietic stem cells, such as self-renewal, quiescence, apoptosis, differentiation, and mobilization.Moreover, the growth factors are also responsible for cooperative actions of several other growth factors and other hormones for binding of receptors on these cells.
Hematopoietic stem cells are currently used for treating more than 80 medical diseases, which include diseases of the immune system, blood disorders, metabolic disorders, neurological disorders, genetic disorders, and several types of cancers, including leukemia and lymphoma. Further, extensively increasing number of product launches for the stem cell therapies is further extended to boost the market growth. For instance, in December 2019, CEVEC and CellGenix announced launch of GMP TGF-1 for the cell and gene therapy industry. Such product launches are anticipated to boost the growth of the GMP cytokines market during the forecast period.
Based on type, the GMP cytokines market is segmented into TNF, interleukins, growth factors, and others.The growth factors segment held the largest share of the market in 2019; whereas, the TNF segment is anticipated to register the highest CAGR in the market during the forecast period.
The growth factors segment held the largest share owing to high demand for cell culture-based research in the field of wound management, oncology, cardiovascular, and other medical fields.For instance, the study ‘Advances in surgical applications of growth factors for wound healing’ was published in April 2019 and was conducted in Shimane University Faculty of Medicine, Japan.
The GMP cytokines market, by configuration, is segmented into cell/gene therapy, tissue-engineered products, others. The cell and gene therapy segment held the largest share of the market in 2019; whereas, the tissue-engineered products segment is anticipated to register the highest CAGR in the market during the forecast period.
The World Health Organization, National Health Service, Centers for Disease Control and Prevention, King Abdullah International Medical Research Center, and Japanese Society of Molecular Cell Biology of Macrophages, along with company websites, are the major primary and secondary sources referred to while preparing this report.
Our reports have been used by over 10K customers, including:
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
Melanoma - Epidemiology Forecast to 2029
Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World Health Organization, 2017).Melanocytes are embryological derivatives of neural crest tissue, and...
The North America organoids market is expected to reach US$ 1,406.47 million by 2027 from US$ 291.39 million in 2019. The market is anticipated to grow at a CAGR of 21.7% from 2020 to 2027. Growth of the North America organoids market is attributed to emergence of three-dimensional (3D) organoids and rise in investments in research. However,...
The Europe organoids market is projected to reach US$ 1,260.08 million by 2027 from US$ 247.85 million in 2019; it is estimated to grow at a CAGR of 22.5% from 2020 to 2027. Increasing demand for tumor modelling and biobanking and rising adoption of personalized drugs are expected to drive the market. Personalized medicine is a growing...
The Middle East & Africa organoids market is expected to reach US$ 141.26 million in 2027 from US$ 37.34 million in 2019; the market is estimated to grow at a CAGR of 20.9% from 2020 to 2027. The growth of the market can be attributed to growing research on organoids in the Middle East & Africa region and rising focus on developing alternatives...
The South and Central America nurse call systems market is expected to reach US$ 200.11 million by 2027 from US$ 87.23 million in 2019. The market is estimated to grow at a CAGR of 10.8% from 2020-2027. The growth of the South and Central America nurse call systems market is driven by the growing incidence of Alzheimer’s disease and dementia...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
573 pages •
By Global Industry Analysts
• Apr 2021
- Looking Beyond Today’s Challenges to Tomorrow’s Healthcare Needs. Genetic Testing to Reach $18.9 Billion as the Burden of Non-Communicable Diseases Grows Bigger
- The global market for Genetic Testing is forecast to reach US$18.9 billion by the year 2027, trailing a post COVID-19 CAGR of 8.6% over the...
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.